Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat
Andrew J.S. Coats, Heli Tolppanen
Topics & Concepts
Heart failureMedicineEjection fractionCyclic guanosine monophosphateInternal medicineCardiologyPlaceboClinical endpointAfterloadPopulationAdverse effectPharmacologyNitric oxideClinical trialBlood pressurePathologyEnvironmental healthAlternative medicineHeart Failure Treatment and ManagementNitric Oxide and Endothelin EffectsCardiovascular Function and Risk Factors